USE OF ZOLEDRONIC ACID AND A RАNK LIGAND INHIBITOR IN THE PALLIATIVE TREATMENT OF CANCERS OF THE PROSTATE WITH BONE METASTASES

• Main Authors: S. V. Mushigin, D. G. Sokov, I. G. Rusakov
• Format: Article
• Language: Russian
• Published: ABV-press 2014-07-01
• Series: Onkourologiâ
• Subjects: cancer; bone metastases; pain syndrome; resorption; mineral bone density; bisphonates; zoledronic acid; denosumab
• Online Access: http://oncourology.abvpress.ru/index.php/oncur/article/view/147

<p>In the metastatic patterns of the cancer, the tumor foci are located more frequently in the tubular bones and vertebral column, just less frequently in the bones of the pelvis, and even more rarely in those of the shoulder and skull. Bone pain is usually related to the involvement of the periosteum that has an extensive network of nociceptors. Auxiliary exposures that directly affect the intensity of pain syndrome and the strength of bone structures are used in addition to basic therapy options for cancer of the prostate. Among these agents there are bisphosphonates. Once ingested, bisphosphonates are transported by blood to the areas of active bone tissue rearrangement where they are tightly bound to the mineral matrix. Their administration causes a considerable reduction in pain syndrome, a decrease in the frequency of complications of bone metastases, and an increase in time before a first bone complication. Antiresorptive therapy including particularly zoledronic acid (resorba) or denosumab is a necessary treatment option in the above category of patients with bone metastases.</p>